Innovative Treatment Approaches in AML
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 266
Special Issue Editors
Interests: AML; allogeneic HSCT; poor graft function; maintenance treatment
Special Issues, Collections and Topics in MDPI journals
Interests: molecular pathogenesis of acute leukemia; management in elderly; novel targeted agents; haploidentical HSCT
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) has undergone major revolutions in the areas of diagnosis, prognostication and treatment approaches over the last decade. Recent advances include a better insight into disease pathobiology obtained by advanced mutational profiling, minimal residual disease detection, novel targeted therapeutic agents and combination strategies. In fact, the European LeukemiaNet (ELN) recommendations have recently been revised. These current advancements allow for the more precise risk stratification of the patient and enable personalized treatment possibilities in different settings, namely upon diagnosis, in the context of allogeneic hematopoietic stem cell transplantation (HSCT) and in relapse, even in elderly patients.
We are pleased to invite you to contribute to the Special Issue “Innovative Treatment Approaches in AML”. Its aim is to discuss novel diagnostic and treatment strategies during the entire path of AML treatment in different settings.
Original research articles and reviews are welcome. We would like to collaborate with you to ensure the success of this Special Issue. Research areas may include (but are not limited to) the following: insights into molecular pathogenesis and biology, diagnostic algorithms, clinical trials, novel therapeutic targets, immunotherapy and guideline recommendations for diagnosis and management in the era of novel, drugs as well as novel HSCT strategies.
We look forward to receiving your contributions.
Dr. Semra Aydin
Dr. Raheel Iftikhar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- AML treatment
- allogeneic HSCT
- novel targeted therapeutic agents
- diagnostic
- treatment strategies.
